Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
<p>Water plot of best response in lung NEN.</p>
Sparad:
| Huvudupphovsman: | Dwight H. Owen (15034782) (author) |
|---|---|
| Övriga upphovsmän: | Brooke Benner (15054338) (author), Lai Wei (15023852) (author), Vineeth Sukrithan (15054341) (author), Ashima Goyal (15054344) (author), Ye Zhou (15054347) (author), Carly Pilcher (15054350) (author), Sheryl-Ann Suffren (15054353) (author), Gwen Christenson (15054356) (author), Nancy Curtis (15054359) (author), Megan Jukich (15054362) (author), Emily Schwarz (15054365) (author), Himanshu Savardekar (15054368) (author), Ruthann Norman (15054371) (author), Sarah Ferguson (15054374) (author), Barbara Kleiber (15054377) (author), Robert Wesolowski (8863505) (author), William E. Carson (15054380) (author), Gregory A. Otterson (15054383) (author), Claire F. Verschraegen (15054386) (author), Manisha H. Shah (15054389) (author), Bhavana Konda (15054392) (author) |
| Publicerad: |
2025
|
| Ämnen: | |
| Taggar: |
Lägg till en tagg
Inga taggar, Lägg till första taggen!
|
Liknande verk
Liknande verk
-
Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
av: Dwight H. Owen (15034782)
Publicerad: (2025) -
Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
av: Dwight H. Owen (15034782)
Publicerad: (2025) -
Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
av: Dwight H. Owen (15034782)
Publicerad: (2025) -
Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
av: Dwight H. Owen (15034782)
Publicerad: (2025) -
Supplementary Table S2 from A Phase II Trial of Guadecitabine in Children and Adults with SDH-Deficient GIST, Pheochromocytoma, Paraganglioma, and HLRCC-Associated Renal Cell Carcinoma
av: John A. Ligon (15024477)
Publicerad: (2025)